NF-κB-mediated modulation of inducible nitric oxide synthase activity controls induction of the epstein-barr virus productive cycle by transforming growth factor beta

Journal of Virology

Volumn 85, Issue 13, 2011, Pages 6502-6512

  Oussaief, Lassad ^a,d   Ramírez, Vanessa ^b,e   Hippocrate, Aurélie ^a   Arbach, Hratch ^b   Cochet, Chantal ^b   Proust, Alexis ^c   Raphaël, Martine ^c   Khelifa, Ridha ^d   Joab, Irène ^a  

^a INSERM U1014   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d HABIB THAMEUR HOSPITAL   (Tunisia)

^e UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSFORMING GROWTH FACTOR BETA1; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; MAPK1 PROTEIN, HUMAN; NITRIC OXIDE; NOS2A PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EPSTEIN BARR VIRUS; INNATE IMMUNITY; LATENT VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIROGENESIS; VIRUS CELL INTERACTION; B LYMPHOCYTE; BIOSYNTHESIS; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

HUMAN HERPESVIRUS 4;

B-LYMPHOCYTES; CELL LINE; CELL LINE, TRANSFORMED; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA1; VIRUS ACTIVATION;

EID: 80052057357     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02560-10     Document Type: Article

References (52)

1. Agresti, A., R. Lupo, M. E. Bianchi, and S. Muller. 2003. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem. Biophys. Res. Commun. 302:421-426.
2. Arbach, H., et al. 2006. Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J. Virol. 80:845-853.
3. Arsura, M., et al. 2003. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene 22:412-425.
4. Bierie, B., and H. L. Moses. 2006. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6:506-520.
5. Bonavida, B., and S. Baritaki. 2011. Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-kappaB/Snail/YY1/RKIP circuitry. Nitric Oxide 24:1-11.
6. Callahan, J. F., et al. 2002. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J. Med. Chem. 45:999-1001.
7. Dai, R., et al. 2008. Suppression of LPS-induced interferon-gamma and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation. Blood 112:4591-4597.
8. Davis, R. L., A. C. Sanchez, D. J. Lindley, S. C. Williams, and P. J. Syapin. 2005. Effects of mechanistically distinct NF-kappaB inhibitors on glial inducible nitric-oxide synthase expression. Nitric Oxide 12:200-209.
9. di Renzo, L., A. Altiok, G. Klein, and E. Klein. 1994. Endogenous TGF-beta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines. Int. J. Cancer 57:914-919.
10. El Mchichi, B., A. Hadji, A. Vazquez, and G. Leca. 2007. p38 MAPK and MSK1 mediate caspase-8 activation in manganese-induced mitochondriadependent cell death. Cell Death Differ. 14:1826-1836.
11. Fahmi, H., C. Cochet, Z. Hmama, P. Opolon, and I. Joab. 2000. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J. Virol. 74:5810-5818.
12. Gao, X., K. Ikuta, M. Tajima, and T. Sairenji. 2001. 12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase. Virology 286:91-99.
13. Goumans, M. J., et al. 2003. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol. Cell 12:817- 828.
14. Grau, A. M., P. K. Datta, J. Zi, S. K. Halder, and R. D. Beauchamp. 2006. Role of Smad proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells. Cell Signal. 18:1041-1050.
15. Grivennikov, S. I., and M. Karin. 2010. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21:11-19.
16. Gruffat, H., E. Manet, and A. Sergeant. 2002. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep. 3:141-146.
17. Gutsch, D. E., et al. 1994. The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NFkappa B. Mol. Cell. Biol. 14:1939-1948.
18. Hiscott, J., H. Kwon, and P. Genin. 2001. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J. Clin. Invest. 107:143-151.
19. Inman, G. J., U. K. Binne, G. A. Parker, P. J. Farrell, and M. J. Allday. 2001. Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J. Virol. 75: 2400-2410.
20. Inman, G. J., et al. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62:65-74.
21. Kadowaki, S., et al. 2004. Down-regulation of inducible nitric oxide synthase by lysophosphatidic acid in human respiratory epithelial cells. Mol. Cell. Biochem. 262:51-59.
22. Kamon, J., et al. 2004. A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochem. Biophys. Res. Commun. 323:242-248.
23. Kenney, S. 2007. Reactivation and lytic replication of EBV. In C.-F. G. Arvin, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley, and K. Yamanishi (ed.), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
24. Kieff, E. 2007. Epstein-Barr virus and its replication, vol. 2. Lippincott William & Wilkins, Philadelphia, PA.
25. Lu, C. C., et al. 2006. Genome-wide transcription program and expression of the Rta responsive gene of Epstein-Barr virus. Virology 345:358-372.
26. Mannick, J. B., K. Asano, K. Izumi, E. Kieff, and J. S. Stamler. 1994. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79:1137-1146.
27. Massague, J., and D. Wotton. 2000. Transcriptional control by the TGFbeta/Smad signaling system. EMBO J. 19:1745-1754.
28. Mizel, S. B., A. N. Honko, M. A. Moors, P. S. Smith, and A. P. West. 2003. Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J. Immunol. 170:6217-6223.
29. Mogensen, T. H., J. Melchjorsen, P. Hollsberg, and S. R. Paludan. 2003. Activation of NF-kappa B in virus-infected macrophages is dependent on mitochondrial oxidative stress and intracellular calcium: downstream involvement of the kinases TGF-beta-activated kinase 1, mitogen-activated kinase/extracellular signal-regulated kinase kinase 1, and I kappa B kinase. J. Immunol. 170:6224-6233.
30. Mogensen, T. H., and S. R. Paludan. 2001. Molecular pathways in virusinduced cytokine production. Microbiol. Mol. Biol. Rev. 65:131-150.
31. Nagata, Y., et al. 2004. Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients. Immunology 111:223-229.
32. Niller, H. H., et al. 2004. EBV-associated neoplasms: alternative pathogenetic pathways. Med. Hypotheses 62:387-391.
33. Oliveira, J. B., et al. 2007. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc. Natl. Acad. Sci. U. S. A. 104:8953- 8958.
34. Onai, Y., et al. 2004. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc. Res. 63:51-59.
35. Oussaief, L., et al. 2009. Activation of the lytic program of the Epstein-Barr virus in Burkitt's lymphoma cells leads to a two steps downregulation of expression of the proapoptotic protein BimEL, one of which is EBV-lategene expression dependent. Virology 387:41-49.
36. Oussaief, L., et al. 2009. Phosphatidylinositol 3-kinase/Akt pathway targets acetylation of Smad3 through Smad3/CREB-binding protein interaction: contribution to transforming growth factor beta1-induced Epstein-Barr virus reactivation. J. Biol. Chem. 284:23912-23924.
37. Pfeffer, S., et al. 2005. Identification of microRNAs of the herpesvirus family. Nat. Methods 2:269-276.
38. Saito, N., et al. 2003. Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-kappaB through distinct signaling pathways in fibroblast cell lines. J. Biol. Chem. 278:46565-46575.
39. Sanchez-Capelo, A. 2005. Dual role for TGF-beta1 in apoptosis. Cytokine Growth Factor Rev. 16:15-34.
40. Santoro, M. G., A. Rossi, and C. Amici. 2003. NF-kappaB and virus infection: who controls whom. EMBO J. 22:2552-2560.
41. Shi, Y., and J. Massague. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700.
42. Soni, V., E. Cahir-McFarland, and E. Kieff. 2007. LMP1 TRAFficking activates growth and survival pathways. Adv. Exp. Med. Biol. 597:173-187.
43. Thompson, M. P., and R. Kurzrock. 2004. Epstein-Barr virus and cancer. Clin. Cancer Res. 10:803-821.
44. Urier, G., M. Buisson, P. Chambard, and A. Sergeant. 1989. The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J. 8:1447-1453.
45. Vodovotz, Y., C. Bogdan, J. Paik, Q. W. Xie, and C. Nathan. 1993. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med. 178:605-613.
46. Wan, F., et al. 2007. Ribosomal protein S3: a KH domain subunit in NFkappaB complexes that mediates selective gene regulation. Cell 131:927-939.
47. Wang, X., et al. 2009. Inducible nitric-oxide synthase expression is regulated by mitogen-activated protein kinase phosphatase-1. J. Biol. Chem. 284: 27123-27134.
48. Yin, Q., K. Jupiter, and E. K. Flemington. 2004. The Epstein-Barr virus transactivator Zta binds to its own promoter and is required for full promoter activity during anti-Ig and TGF-beta1 mediated reactivation. Virology 327:134-143.
49. Yuan, J., E. Cahir-McFarland, B. Zhao, and E. Kieff. 2006. Virus and cell RNAs expressed during Epstein-Barr virus replication. J. Virol. 80:2548- 2565.
50. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cellspecific mechanism. Proc. Natl. Acad. Sci. U. S. A. 93:9194-9199.
51. Zhang, Y., X. Feng, R. We, and R. Derynck. 1996. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature 383: 168-172.
52. Zhou, R., G. Hu, A. Y. Gong, and X. M. Chen. 2010. Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells. Nucleic Acids Res. 38:3222-3232.